Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Journal Article
PMID (41679466)
Authors Fizazi K, Attard G, Azad AA, Baciarello G, Beltran H, Bjartell A, Blanchard P, Bossaert F, Castro E, Compérat E, de Bono J, Deschamps A, Efstathiou E, Emmett L, Fanti S, Fonteyne V, González-Del-Alba A, Gravis G, James ND, Kanesvaran R, McDermott RS, Mehra N, Parker C, Renard-Penna RM, Rubin MA, Saad F, Sweeney C, Tilki D, Tombal B, Tree AC, Walz J, Zilli T, Gillessen S, ESMO Guidelines Committee
Title Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Journal Vol Issue Date Pages Journal Short Title
Annals of oncology : official journal of the European Society for Medical Oncology 2026 Feb 10 Ann Oncol
URL
Abstract Text

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PALB2 inact mut prostate cancer sensitive Rucaparib Guideline Actionable Rubraca (rucaparib) is included in guidelines for patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations (PMID: 41679466; ESMO.org). detail... 41679466
MSH6 negative prostate cancer sensitive Nivolumab Guideline Actionable PDCD1 (PD-1) or CD274 (PD-L1) inhibitors, including Opdivo (nivolumab) is included in guidelines for patients with metastatic castration-resistant prostate cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 41679466; ESMO.org). detail... 41679466
MLH1 negative prostate cancer sensitive Durvalumab Guideline Actionable PDCD1 (PD-1) or CD274 (PD-L1) inhibitors, including Imfinzi (durvalumab) is included in guidelines for patients with metastatic castration-resistant prostate cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 41679466; ESMO.org). detail... 41679466
MSH6 negative prostate cancer sensitive Pembrolizumab Guideline Actionable PDCD1 (PD-1) or CD274 (PD-L1) inhibitors, including Keytruda (pembrolizumab) is included in guidelines for patients with metastatic castration-resistant prostate cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 41679466; ESMO.org). 41679466 detail...
PALB2 inact mut prostate cancer sensitive Enzalutamide + Talazoparib Guideline Actionable Talzenna (talazoparib) plus Xtandi (enzalutamide) is included in guidelines for patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations (PMID: 41679466; ESMO.org). detail... 41679466
PALB2 inact mut prostate cancer sensitive Abiraterone + Niraparib Guideline Actionable Zejula (niraparib) plus Zytiga (abiraterone) is included in guidelines for patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations (PMID: 41679466; ESMO.org). 41679466 detail...
PALB2 inact mut prostate cancer sensitive Abiraterone + Olaparib Guideline Actionable Lynparza (olaparib) plus Zytiga (abiraterone) is included in guidelines for patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations (PMID: 41679466; ESMO.org). 41679466 detail...
MLH1 negative prostate cancer sensitive Pembrolizumab Guideline Actionable PDCD1 (PD-1) or CD274 (PD-L1) inhibitors, including Keytruda (pembrolizumab) is included in guidelines for patients with metastatic castration-resistant prostate cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 41679466; ESMO.org). 41679466 detail...
PALB2 inact mut prostate cancer sensitive Olaparib Guideline Actionable Lynparza (olaparib) is included in guidelines for patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations (PMID: 41679466; ESMO.org). 41679466 detail...
MLH1 negative prostate cancer sensitive Nivolumab Guideline Actionable PDCD1 (PD-1) or CD274 (PD-L1) inhibitors, including Opdivo (nivolumab) is included in guidelines for patients with metastatic castration-resistant prostate cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 41679466; ESMO.org). detail... 41679466
MSH6 negative prostate cancer sensitive Durvalumab Guideline Actionable PDCD1 (PD-1) or CD274 (PD-L1) inhibitors, including Imfinzi (durvalumab) is included in guidelines for patients with metastatic castration-resistant prostate cancer with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (PMID: 41679466; ESMO.org). 41679466 detail...